论文信息 - A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents - 字舞流文

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

M. Andreeff | G. Garcia-Manero | J. Cortes | Xuelin Huang | K. Patel | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | R. Kanagal-Shamanna | N. Jain | N. Short | Y. Alvarado | M. Ohanian | G. Montalban-Bravo | P. Bose | H. Kantarjian | M. Muftuoglu | W. Qiao | G. Issa | L. Nasr | F. Ong | W. Macaron | R. Delumpa | Mahesh Basyal | R. Abramova